taurine has been researched along with Recrudescence in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We believe that peritoneal catheter taurolidine lock could be considered in cases of relapsing or refractory peritonitis, as it could prevent catheter removal and permanent switch to hemodialysis in selected cases, although literature is scarce and further studies are needed." | 8.02 | Relapsing peritonitis and taurolidine peritoneal catheter lock: One center experience. ( Álvarez Nadal, M; Burguera Vion, V; Campillo Trapero, C; Fernández Lucas, M; López Melero, E; Rivera Gorrín, ME; Sosa Barrios, RH, 2021) |
| "Naltrexone and acamprosate may ultimately prove to be useful additions to pharmacotherapy for alcoholism by reducing relapse." | 4.82 | Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. ( Littleton, J; Zieglgänsberger, W, 2003) |
| "We believe that peritoneal catheter taurolidine lock could be considered in cases of relapsing or refractory peritonitis, as it could prevent catheter removal and permanent switch to hemodialysis in selected cases, although literature is scarce and further studies are needed." | 4.02 | Relapsing peritonitis and taurolidine peritoneal catheter lock: One center experience. ( Álvarez Nadal, M; Burguera Vion, V; Campillo Trapero, C; Fernández Lucas, M; López Melero, E; Rivera Gorrín, ME; Sosa Barrios, RH, 2021) |
| "105 patients with severe alcohol dependence, who were treated in 13 centers in Switzerland, took part in this open study." | 2.70 | [Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland]. ( Fuchs, WJ; Riebenfeld, D, 2002) |
| "94 acamprosate-treated and 85 placebo-treated patients completed the treatment phase: of those withdrawn, 104 (52 in each group) relapsed, 69 (33 vs 36, respectively) were lost to follow-up, 63 (31 vs 32) refused to continue treatment, 16 (15 vs 11) had concurrent illness, three (two vs one) died, ten (six vs four) had adverse side-effects, one (acamprosate treated) received the wrong medication, and three (placebo treated) were non-compliant." | 2.68 | Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. ( Fischer, F; Fleischhacker, WW; Lesch, OM; Nimmerrichter, A; Oberbauer, H; Platz, T; Potgieter, A; Walter, H; Whitworth, AB, 1996) |
| "Acamprosate proved to be a safe and effective aid in treating alcohol-dependent patients and in maintaining the abstinence of patients during 2 years." | 2.68 | Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. ( Mann, K; Sass, H; Soyka, M; Zieglgänsberger, W, 1996) |
| "Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions." | 2.68 | Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. ( Gavrilovic, M; Le Bon, O; Lehert, P; Lion, K; Pelc, I; Verbanck, P, 1997) |
| "Acamprosate was associated with a reduction in risk of discontinuing treatment for Europe (RR = 0." | 2.52 | The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. ( Donoghue, K; Drummond, C; Elzerbi, C; Pilling, S; Saunders, R; Whittington, C, 2015) |
| "Globally, alcohol abuse and dependence are significant contributors to chronic disease and injury and are responsible for nearly 4% of all deaths annually." | 2.50 | The development of acamprosate as a treatment against alcohol relapse. ( Kufahl, PR; Olive, MF; Watterson, LR, 2014) |
| "Relapse prevention for alcohol dependence has traditionally involved psychosocial and psychotherapeutic interventions." | 2.43 | Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. ( Jung, YC; Namkoong, K, 2006) |
| "Acamprosate is a relatively new drug that appears to be clinically useful in the treatment of alcohol dependence." | 2.39 | Acamprosate in alcohol dependence: how does it work? ( Littleton, J, 1995) |
| "Standard treatment for alcohol abuse may include pharmacotherapy to alleviate withdrawal symptoms followed by psychotherapy in inpatient and/or outpatient settings." | 2.39 | The pharmacological treatment of alcohol dependence: needs and possibilities. ( Mann, K, 1996) |
| "Treatment with neramexane that shares part of the pharmacological effects of acamprosate on NMDA receptors, however, resulted in a nonselective reduction of lever responding." | 1.33 | The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. ( Bachteler, D; Ciccocioppo, R; Danysz, W; Economidou, D; Spanagel, R, 2005) |
| "Alcohol relapse is a major problem in the treatment of alcohol abuse and alcoholism." | 1.31 | Central nervous system mechanisms in alcohol relapse. ( Le, AD; McBride, WJ; Noronha, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.30) | 18.7374 |
| 1990's | 13 (30.23) | 18.2507 |
| 2000's | 12 (27.91) | 29.6817 |
| 2010's | 10 (23.26) | 24.3611 |
| 2020's | 4 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Melugin, PR | 1 |
| Wu, F | 1 |
| Munoz, C | 1 |
| Phensy, A | 1 |
| Pradhan, G | 1 |
| Luo, Y | 1 |
| Nofal, A | 1 |
| Manepalli, R | 1 |
| Kroener, S | 1 |
| Sosa Barrios, RH | 1 |
| Álvarez Nadal, M | 1 |
| Burguera Vion, V | 1 |
| Campillo Trapero, C | 1 |
| López Melero, E | 1 |
| Fernández Lucas, M | 1 |
| Rivera Gorrín, ME | 1 |
| Lannoy, D | 1 |
| Janes, A | 1 |
| Lenne, X | 1 |
| Neuville, S | 1 |
| Bourry, J | 1 |
| Odou, P | 1 |
| Bruandet, A | 1 |
| Seguy, D | 1 |
| Tian, J | 1 |
| Song, M | 1 |
| Kaufman, DL | 1 |
| Nyhuis, PW | 1 |
| Niederhofer, E | 1 |
| Scherbaum, N | 2 |
| Schifano, F | 1 |
| Bonnet, U | 1 |
| Dembski, N | 1 |
| Niederhofer, A | 1 |
| Specka, M | 1 |
| Tenbergen, M | 1 |
| Diamanti, A | 1 |
| Capriati, T | 1 |
| Iacono, A | 1 |
| Stout, RL | 1 |
| Braciszewski, JM | 1 |
| Subbaraman, MS | 1 |
| Kranzler, HR | 1 |
| O'Malley, SS | 2 |
| Falk, D | 1 |
| Kufahl, PR | 1 |
| Watterson, LR | 1 |
| Olive, MF | 2 |
| Donoghue, K | 1 |
| Elzerbi, C | 1 |
| Saunders, R | 1 |
| Whittington, C | 1 |
| Pilling, S | 1 |
| Drummond, C | 1 |
| Saitz, R | 1 |
| Witkiewitz, K | 1 |
| Vowles, KE | 1 |
| McCallion, E | 1 |
| Frohe, T | 1 |
| Kirouac, M | 1 |
| Maisto, SA | 1 |
| Kiefer, F | 3 |
| Witt, SH | 1 |
| Frank, J | 1 |
| Richter, A | 1 |
| Treutlein, J | 1 |
| Lemenager, T | 1 |
| Nöthen, MM | 1 |
| Cichon, S | 1 |
| Batra, A | 1 |
| Berner, M | 1 |
| Wodarz, N | 1 |
| Zimmermann, US | 1 |
| Spanagel, R | 4 |
| Wiedemann, K | 2 |
| Smolka, MN | 1 |
| Heinz, A | 2 |
| Rietschel, M | 1 |
| Mann, K | 4 |
| Wölwer, W | 1 |
| Frommann, N | 1 |
| Jänner, M | 1 |
| Franke, PE | 1 |
| Lieb, B | 1 |
| Falkai, P | 1 |
| Wobrock, T | 1 |
| Kuhlmann, T | 1 |
| Radermacher, M | 1 |
| Maier, W | 1 |
| Schütz, C | 2 |
| Ohmann, C | 1 |
| Burtscheidt, W | 1 |
| Gaebel, W | 1 |
| Bujarski, S | 1 |
| Lunny, K | 1 |
| Ray, LA | 1 |
| O'Brien, CP | 1 |
| Littleton, J | 2 |
| Zieglgänsberger, W | 4 |
| Bachteler, D | 1 |
| Economidou, D | 1 |
| Danysz, W | 1 |
| Ciccocioppo, R | 1 |
| Jahn, H | 1 |
| Otte, C | 1 |
| Demiralay, C | 1 |
| Wolf, K | 1 |
| Croissant, B | 1 |
| Diehl, A | 2 |
| Klein, O | 2 |
| Zambrano, S | 1 |
| Nakovics, H | 1 |
| Jung, YC | 1 |
| Namkoong, K | 1 |
| Jiménez-Arriero, MA | 1 |
| Rubio, G | 1 |
| Bowers, MS | 1 |
| Chen, BT | 1 |
| Chou, JK | 1 |
| Osborne, MP | 1 |
| Gass, JT | 1 |
| See, RE | 1 |
| Bonci, A | 1 |
| Janak, PH | 1 |
| Whitworth, AB | 1 |
| Fischer, F | 1 |
| Lesch, OM | 1 |
| Nimmerrichter, A | 1 |
| Oberbauer, H | 1 |
| Platz, T | 1 |
| Potgieter, A | 1 |
| Walter, H | 1 |
| Fleischhacker, WW | 1 |
| Sass, H | 1 |
| Soyka, M | 2 |
| Kotter, G | 1 |
| Preuss, U | 1 |
| Pelc, I | 2 |
| Verbanck, P | 1 |
| Le Bon, O | 1 |
| Gavrilovic, M | 1 |
| Lion, K | 1 |
| Lehert, P | 1 |
| Kratzer, U | 1 |
| Schmidt, WJ | 1 |
| Sillaber, I | 1 |
| Corrigall, WA | 1 |
| Stewart, J | 1 |
| Shaham, Y | 1 |
| Schädlich, PK | 1 |
| Brecht, JG | 1 |
| Malerich, JA | 1 |
| Oberpichler-Schwenk, H | 1 |
| Yarborough, WH | 1 |
| McBride, WJ | 1 |
| Le, AD | 1 |
| Noronha, A | 1 |
| Fuchs, WJ | 1 |
| Riebenfeld, D | 1 |
| Zawadziński, S | 1 |
| Benke, G | 1 |
| Eluszkiewicz, S | 1 |
| Wasikowski, A | 1 |
| Zarek, S | 1 |
| Lhuintre, JP | 1 |
| Daoust, M | 1 |
| Moore, ND | 1 |
| Chretien, P | 1 |
| Saligaut, C | 1 |
| Tran, G | 1 |
| Bosimare, F | 1 |
| Hillemand, B | 1 |
| Bijleveld, CM | 1 |
| Vonk, RJ | 1 |
| Kuipers, F | 1 |
| Havinga, R | 1 |
| Fernandes, J | 1 |
| Bergamini, L | 1 |
| Mutani, R | 1 |
| Delsedime, M | 1 |
| Durelli, L | 1 |
| Admirand, WH | 1 |
| Earnest, DL | 1 |
| Williams, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse[NCT02423772] | 37 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial[NCT00590642] | 30 participants (Anticipated) | Observational | 2006-04-30 | Completed | |||
| Campral (Acamprosate) Treatment of Alcohol Dependence in a Family Medicine Setting: A Randomized, Double-Blind Placebo-Controlled Study[NCT00381043] | Phase 4 | 100 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
% of individuals with evidence for 80% compliance with medication based on returned blister packs and weekly diaries. (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1- Acamprosate | 93.3 |
| 2 - Sugar Pill - Placebo | 91.6 |
Percentage of participants who dropped out of study by drug condition (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1- Acamprosate | 21.5 |
| 2 - Sugar Pill - Placebo | 16.3 |
% of Heavy drinking days (5 or more drinks/d for a man or 4 or more drinks/d for a woman) over the 12 weeks of the trial. (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of heavy drinking days (Mean) |
|---|---|
| 1- Acamprosate | 15.8 |
| 2 - Sugar Pill - Placebo | 18.4 |
Range of overall severity of illness: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill (NCT00381043)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| 1- Acamprosate | 2.3 |
| 2 - Sugar Pill - Placebo | 2.4 |
%Days without any alcohol consumption over the treatment period (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| 1- Acamprosate | 40.7 |
| 2 - Sugar Pill - Placebo | 41.6 |
% of subjects with no drinking during the 12 week treatment trial (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1- Acamprosate | 5.9 |
| 2 - Sugar Pill - Placebo | 19.1 |
Number of individuals retained in the trial by acamprosate vs placebo group (NCT00381043)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| 1- Acamprosate | 39 |
| 2 - Sugar Pill - Placebo | 41 |
10 reviews available for taurine and Recrudescence
| Article | Year |
|---|---|
The development of acamprosate as a treatment against alcohol relapse.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Humans; Recurrence; Taurine | 2014 |
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Europe; Female; Global Health; Humans; Male; Mid | 2015 |
Research advances in the understanding and treatment of addiction.
Topics: Acamprosate; Alcohol Deterrents; Brain; Chronic Disease; Disease Progression; Humans; Naltrexone; Na | 2003 |
Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Brain; Humans; Naltrexone; N | 2003 |
Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; gamma-Aminobutyric Acid; Glutamine; Humans; | 2006 |
Acamprosate in alcohol dependence: how does it work?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Mo | 1995 |
[Pharmacotherapy of alcoholism].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Dopamine Agents; Hum | 1996 |
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans | 1997 |
[Alcoholism: relapse prevention].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Humans; Medical History Taki | 1997 |
The pharmacological treatment of alcohol dependence: needs and possibilities.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Humans; Recurrence; Taurine | 1996 |
12 trials available for taurine and Recrudescence
| Article | Year |
|---|---|
Effectiveness of Psychoanalytic-Interactional Group Therapy vs. Behavioral Group Therapy in Routine Outpatient Treatment of Alcohol-Dependent Patients.
Topics: Acamprosate; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Disulfiram; Female | 2018 |
What happens when people discontinue taking medications? Lessons from COMBINE.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Mod | 2014 |
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therap | 2015 |
The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cou | 2011 |
The effects of drinking goal on treatment outcome for alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; | 2013 |
Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Leptin; Mal | 2005 |
A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Anticonvulsants; Carbamazepine; Female; Humans; | 2006 |
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.
Topics: Acamprosate; Adult; Alcoholism; Double-Blind Method; Ethanol; Female; Follow-Up Studies; Humans; Mal | 1996 |
Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Follow-Up Studi | 1996 |
Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Diarrhea; Dose-Response Relati | 1997 |
[Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Female; Humans; Male; | 2002 |
Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics.
Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Erythrocyte Indices; | 1985 |
21 other studies available for taurine and Recrudescence
| Article | Year |
|---|---|
The effects of acamprosate on prefrontal cortical function are mimicked by CaCl2 and they are influenced by the history of alcohol exposure.
Topics: Acamprosate; Animals; Calcium; Calcium Chloride; Ethanol; Mice; Prefrontal Cortex; Recurrence; Tauri | 2022 |
Relapsing peritonitis and taurolidine peritoneal catheter lock: One center experience.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Catheter-Related Infections; Catheterization; | 2021 |
Cost-effectiveness of taurolidine locks to prevent recurrent catheter-related blood stream infections in adult patients receiving home parenteral nutrition: a 2-year mirror-image study.
Topics: Adult; Catheter-Related Infections; Catheterization, Central Venous; Central Venous Catheters; Chemo | 2021 |
Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis.
Topics: Animals; Antigen Presentation; Antigen-Presenting Cells; Cell Proliferation; Central Nervous System; | 2021 |
Recurrent catheter related bloodstream infections by Candida glabrata: successful treatment with taurolidine.
Topics: Anti-Infective Agents; Candida glabrata; Candidiasis; Catheter-Related Infections; Humans; Recurrenc | 2014 |
[Acamprosate and naltrexone: similar efficacy for relapse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Recurrence; T | 2014 |
Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Alcohols; Atrial Natriuretic Factor; Female; GAT | 2011 |
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Conditioning, Operant; Cues; Cyclopentan | 2005 |
Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; | 2008 |
Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.
Topics: Acamprosate; Alcohol Deterrents; Animals; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; C | 2007 |
The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats.
Topics: Acamprosate; Alcohol Deterrents; Analgesics, Opioid; Animals; Conditioning, Psychological; Drug Inte | 1998 |
Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress.
Topics: Acamprosate; Animals; Drug Interactions; Drug Tolerance; Food Deprivation; Heroin; Heroin Dependence | 1998 |
The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cost-Benefit Analysis; Economics, Pharmaceutical; Germa | 1998 |
Prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family; Humans; Naltrexon | 1999 |
[Efficient prevention of relapse with acamprosate].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Recurrence; Taurine | 2000 |
Addiction medicine for the primary care physician.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Antidepressive Agents, Tricyclic; | 2001 |
Central nervous system mechanisms in alcohol relapse.
Topics: Acamprosate; Alcoholism; Animals; Behavior; Central Nervous System; Corticotropin-Releasing Hormone; | 2002 |
["Taurolin-Gel" and Taurolin-Trockengel" in treatment of osseous tissue inflammation].
Topics: Anti-Infective Agents, Local; Chronic Disease; Gels; Humans; Osteitis; Recurrence; Taurine; Thiadiaz | 1990 |
Benign recurrent intrahepatic cholestasis: a long-term follow-up study of two patients.
Topics: Bile Acids and Salts; Bilirubin; Calcium Phosphates; Child; Cholestasis, Intrahepatic; Cholestyramin | 1989 |
First clinical experience on the antiepileptic action of taurine.
Topics: Adolescent; Adult; Child; Drug Evaluation; Electroencephalography; Epilepsy; Epilepsy, Tonic-Clonic; | 1974 |
Hyperoxaluria and bowel disease.
Topics: Calcium Metabolism Disorders; Glycolates; Humans; Ileum; Intestinal Diseases; Kidney Calculi; Liver; | 1971 |